ArticleScientific reports2017
Formulation and candidacidal activity of magnetic nanoparticles coated with cathelicidin LL-37 and ceragenin CSA-13.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Comprehensive Insights into Sugar Transporters ofJournal of fungi (Basel, Switzerland) · 2026Article
- Characterization and Phenolic Profiling of AnticandidalACS omega · 2025Article
- Biological properties of ceragenin-coated metal nanoparticles - future challenges and perspectives in clinical practice.Nanomedicine (London, England) · 2025Review
- Bactericidal activity of ceragenin CSA-13, CSA-44 and CSA-131 against bacteria causing bloodstream infections.Frontiers in microbiology · 2025Article
- Natural Antimicrobial Peptides and Their Synthetic Analogues for Effective Oral Microflora Control and Oral Infection Treatment-The Role of Ceragenins in the Development of New Therapeutic Methods.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Fungal vaccines and adjuvants: a tool to reveal the interaction between host and fungi.Archives of microbiology · 2024Review
- Efficacy of Ceragenins in Controlling the Growth of Oral Microorganisms: Implications for Oral Hygiene Management.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Antifungal properties of cathelicidin LL-37: current knowledge and future research directions.World journal of microbiology & biotechnology · 2023Review
- Improving the Hydrophobicity of Plasticized Polyvinyl Chloride for Use in an Endotracheal Tube.Materials (Basel, Switzerland) · 2023Article
- Biofilm-associated genes as potential molecular targets of nano-FePharmacological reports : PR · 2023Article
- Nanomaterials and Coatings for Managing Antibiotic-Resistant Biofilms.Antibiotics (Basel, Switzerland) · 2023Review
- Metallic Nanosystems in the Development of Antimicrobial Strategies with High Antimicrobial Activity and High Biocompatibility.International journal of molecular sciences · 2023Review
- Role of antimicrobial peptide cathelicidin in thrombosis and thromboinflammation.Frontiers in immunology · 2023Review
- Ceragenin CSA-13 displays high antibacterial efficiency in a mouse model of urinary tract infection.Scientific reports · 2022Article
- Antifungal Effect of Nanoparticles against COVID-19 Linked Black Fungus: A Perspective on Biomedical Applications.International journal of molecular sciences · 2022Review
- Molecular Mapping of Antifungal Mechanisms Accessing Biomaterials and New Agents to Target Oral Candidiasis.International journal of molecular sciences · 2022Review
- Biocompatible Materials in Otorhinolaryngology and Their Antibacterial Properties.International journal of molecular sciences · 2022Review
- From Marine Metabolites to the Drugs of the Future: Squalamine, Trodusquemine, Their Steroid and Triterpene Analogues.International journal of molecular sciences · 2022Review
- Sustainable synthesis of microwave-assisted IONPs using Spinacia oleracea L. for control of fungal wilt by modulating the defense system in tomato plants.Journal of nanobiotechnology · 2022Article
- Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapy.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infections caused by Candida spp. represent an emerging problem during treatment of immunocompromised patients and those hospitalized with serious principal diseases. The ever-growing number of fungal strains exhibiting drug resistance necessitates the development of novel antimicrobial therapies including those based on membrane-permeabilizing agents and nanomaterials as drug carriers. In this study, the fungicidal activities of LL-37 peptide, ceragenin CSA-13 and its magnetic derivatives (MNP@LL-37, MNP@CSA-13) against laboratory and clinical strains of C. albicans, C. glabrata and C. tropicalis were evaluated. These experiments confirm the high anti-fungal activity of these well-characterized agents mediated by their interaction with the fungal membrane and demonstrate elevated activity following immobilization of LL-37 and CSA-13 on the surface of magnetic nanoparticles (MNPs). Furthermore, MNP-based nanosystems are resistant to inhibitory factors present in body fluids and effectively inhibit formation of fungal biofilm. Simultaneously, synthesized nanostructures maintain immunomodulatory properties, described previously for free LL-37 peptide and CSA-13 substrate and they do not interfere with the proliferation and viability of osteoblasts, confirming their high biocompatibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.